Research programme: antibody therapeutics - Shenzhen Ionova Life Sciences
Alternative Names: Research programme ELatest Information Update: 28 Sep 2024
At a glance
- Originator Shenzhen Ionova Life Sciences Co., Ltd.
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for research development in Cancer in China (Parenteral)
- 21 Aug 2020 Early research in Cancer in China (unspecified route) (Shenzhen Ionova Life Sciences pipeline August 2020)